Logo image of GH

GUARDANT HEALTH INC (GH) Stock Fundamental Analysis

NASDAQ:GH - Nasdaq - US40131M1099 - Common Stock - Currency: USD

39.32  -0.85 (-2.12%)

After market: 39.32 0 (0%)

Fundamental Rating

3

Taking everything into account, GH scores 3 out of 10 in our fundamental rating. GH was compared to 108 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of GH have multiple concerns. GH is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

GH had negative earnings in the past year.
GH had a negative operating cash flow in the past year.
GH had negative earnings in each of the past 5 years.
In the past 5 years GH always reported negative operating cash flow.
GH Yearly Net Income VS EBIT VS OCF VS FCFGH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

Looking at the Return On Assets, with a value of -29.37%, GH is doing worse than 83.33% of the companies in the same industry.
Industry RankSector Rank
ROA -29.37%
ROE N/A
ROIC N/A
ROA(3y)-32.29%
ROA(5y)-25.29%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GH Yearly ROA, ROE, ROICGH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800 -1K

1.3 Margins

GH's Gross Margin of 60.79% is amongst the best of the industry. GH outperforms 81.48% of its industry peers.
GH's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for GH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.32%
GM growth 5Y-1.93%
GH Yearly Profit, Operating, Gross MarginsGH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

3

2. Health

2.1 Basic Checks

GH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GH has been increased compared to 1 year ago.
The number of shares outstanding for GH has been increased compared to 5 years ago.
Compared to 1 year ago, GH has a worse debt to assets ratio.
GH Yearly Shares OutstandingGH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
GH Yearly Total Debt VS Total AssetsGH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of -0.46, we must say that GH is in the distress zone and has some risk of bankruptcy.
GH has a worse Altman-Z score (-0.46) than 78.70% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.46
ROIC/WACCN/A
WACC8.11%
GH Yearly LT Debt VS Equity VS FCFGH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

GH has a Current Ratio of 4.68. This indicates that GH is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of GH (4.68) is better than 94.44% of its industry peers.
A Quick Ratio of 4.36 indicates that GH has no problem at all paying its short term obligations.
GH has a better Quick ratio (4.36) than 92.59% of its industry peers.
Industry RankSector Rank
Current Ratio 4.68
Quick Ratio 4.36
GH Yearly Current Assets VS Current LiabilitesGH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

7

3. Growth

3.1 Past

GH shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.28%.
The Revenue has grown by 31.04% in the past year. This is a very strong growth!
GH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 28.08% yearly.
EPS 1Y (TTM)-0.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.88%
Revenue 1Y (TTM)31.04%
Revenue growth 3Y25.52%
Revenue growth 5Y28.08%
Sales Q2Q%30.16%

3.2 Future

Based on estimates for the next years, GH will show a very strong growth in Earnings Per Share. The EPS will grow by 21.56% on average per year.
The Revenue is expected to grow by 21.80% on average over the next years. This is a very strong growth
EPS Next Y17.87%
EPS Next 2Y15.45%
EPS Next 3Y23.89%
EPS Next 5Y21.56%
Revenue Next Year17.21%
Revenue Next 2Y19.3%
Revenue Next 3Y20.62%
Revenue Next 5Y21.8%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
GH Yearly Revenue VS EstimatesGH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
GH Yearly EPS VS EstimatesGH Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 -6

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GH Price Earnings VS Forward Price EarningsGH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GH Per share dataGH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

GH's earnings are expected to grow with 23.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.45%
EPS Next 3Y23.89%

0

5. Dividend

5.1 Amount

GH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

GUARDANT HEALTH INC

NASDAQ:GH (3/7/2025, 8:00:01 PM)

After market: 39.32 0 (0%)

39.32

-0.85 (-2.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-20 2025-02-20/amc
Earnings (Next)05-07 2025-05-07/amc
Inst Owners102.32%
Inst Owner Change-5%
Ins Owners4.63%
Ins Owner Change0.97%
Market Cap4.85B
Analysts85.63
Price Target55.59 (41.38%)
Short Float %6.66%
Short Ratio3.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.39%
Min EPS beat(2)-18.05%
Max EPS beat(2)-14.73%
EPS beat(4)0
Avg EPS beat(4)-12.44%
Min EPS beat(4)-18.05%
Max EPS beat(4)-7.14%
EPS beat(8)4
Avg EPS beat(8)3.38%
EPS beat(12)6
Avg EPS beat(12)1.33%
EPS beat(16)7
Avg EPS beat(16)0.4%
Revenue beat(2)2
Avg Revenue beat(2)5.46%
Min Revenue beat(2)1.97%
Max Revenue beat(2)8.95%
Revenue beat(4)4
Avg Revenue beat(4)6.31%
Min Revenue beat(4)1.97%
Max Revenue beat(4)8.95%
Revenue beat(8)8
Avg Revenue beat(8)4.49%
Revenue beat(12)9
Avg Revenue beat(12)2.53%
Revenue beat(16)12
Avg Revenue beat(16)2.87%
PT rev (1m)21.5%
PT rev (3m)31.01%
EPS NQ rev (1m)-8.3%
EPS NQ rev (3m)-8.22%
EPS NY rev (1m)1.41%
EPS NY rev (3m)0.88%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)-0.15%
Revenue NY rev (1m)0.68%
Revenue NY rev (3m)0.98%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.57
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.56
EYN/A
EPS(NY)-2.92
Fwd EYN/A
FCF(TTM)-2.23
FCFYN/A
OCF(TTM)-1.94
OCFYN/A
SpS5.99
BVpS-1.13
TBVpS-1.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.37%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.79%
FCFM N/A
ROA(3y)-32.29%
ROA(5y)-25.29%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.32%
GM growth 5Y-1.93%
F-Score3
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 82.77%
Cap/Sales 4.75%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.68
Quick Ratio 4.36
Altman-Z -0.46
F-Score3
WACC8.11%
ROIC/WACCN/A
Cap/Depr(3y)115.32%
Cap/Depr(5y)203.86%
Cap/Sales(3y)8.54%
Cap/Sales(5y)12.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.88%
EPS Next Y17.87%
EPS Next 2Y15.45%
EPS Next 3Y23.89%
EPS Next 5Y21.56%
Revenue 1Y (TTM)31.04%
Revenue growth 3Y25.52%
Revenue growth 5Y28.08%
Sales Q2Q%30.16%
Revenue Next Year17.21%
Revenue Next 2Y19.3%
Revenue Next 3Y20.62%
Revenue Next 5Y21.8%
EBIT growth 1Y21.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year42.92%
EBIT Next 3Y20.12%
EBIT Next 5Y8.8%
FCF growth 1Y20.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.19%
OCF growth 3YN/A
OCF growth 5YN/A